Terence Kee

Terence Kee

Auto-generated profile, based on publicly available information

Terence Kee

Department of Renal Medicine, Singapore General Hospital, Singapore, Singapore

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2023 in The Lancet Regional Health - Southeast Asia
Verified
Journal Article
Open access
JTJackson Tan
Jackson Tan
MKMuhammad Abdul Mabood Khalil
Muhammad Abdul Mabood Khalil
TKTerence Kee
Terence Kee
HTHo Yee Tiong
Ho Yee Tiong
TKTaqi Fakheruddin Toufeeq Khan
Taqi Fakheruddin Toufeeq Khan
VAVathsala Anantharaman
Vathsala Anantharaman
Deceased donor kidney transplantation (DDKT) is common in high income Western countries with high transplantation rates. However, the utilization of deceased organs is suboptimal in Asia, due to a multitude of factors. Coherent policies are integral to the development of DDKT programs and deterrence of commercialization, but most are still at an infancy and formative stage in Asia. This review article identifies the glass ceiling effects of social, cultural, religious, political, and technical factors hampering the progress of DDKT in Asia. Additionally, it reviews the history of policy development in different countries and describes their idiosyncratic barriers and challenges. Lastly, it discusses innovative policy measures that can be undertaken to proliferate DDKT practice and curtail commercialization. The long-term ideal is to achieve regional equity and self-sufficiency, through a shared ethos of social and ethical responsibility that transcends and resonates with the different segments of the Asian community.

24 October 2021 in Singapore Medical Journal
Verified
Journal Article
Open access
QHQuan Yao Ho
Quan Yao Ho
RSRehena Sultana
Rehena Sultana
TLTung Lin Lee
Tung Lin Lee
STSobhana Thangaraju
Sobhana Thangaraju
TKTerence Kee
Terence Kee
HHHtay Htay
Htay Htay
Introduction: The clinical presentation and outcomes of coronavirus disease 2019 (COVID-19) in kidney transplant recipients (KTRs) have not been well studied. Methods: We performed a meta-analysis to examine the presenting features, outcomes and the effect of treatment on outcomes of KTRs with COVID-19. Database search was performed up to 5 September 2020 through PubMed, Embase, Web of Science, Scopus and CENTRAL. Results: Overall, 23 studies (1,373 patients) were included in the review and meta-analysis. The most common presenting symptoms included fever (74.0%, 95% confidence interval [CI] 65.3–81.1), cough (63.3%, 95% CI 56.5–69.6) and dyspnoea (47.5%, 95% CI 39.6–55.6). Pooled rates of mortality and critical illness were 21.1% (95% CI 15.3–28.4) and 27.7% (95% CI 21.5–34.8), respectively. Acute kidney injury occurred in 38.9% (95% CI 30.6–48.1) and dialysis was required in 12.4% (95% CI 8.3–18.0) of the cases. Conclusion: Kidney transplant recipients with COVID-19 have a similar clinical presentation as the general population, but they have higher morbidity and mortality. It is uncertain whether high-dose corticosteroid or hydroxychloroquine reduces the risks of mortality in KTRs with COVID-19.

28 September 2020 in Nephrology
Verified
Journal Article
Closed access
PDF file
YYYun Ting Yap
Yun Ting Yap
QHQuan Yao Ho
Quan Yao Ho
TKTerence Kee
Terence Kee
CNChee Yong Ng
Chee Yong Ng
CCChang Yin Chionh
Chang Yin Chionh

1 September 2020
Verified
Journal Article
Closed access
TKTerence Kee
Terence Kee
VGValerie Gan
Valerie Gan
JSJasmine Chung Shimin
Jasmine Chung Shimin
TSTee Ping Sing
Tee Ping Sing
LMLu York Moi
Lu York Moi
TSTan Chieh Suai
Tan Chieh Suai

11 September 2020 in Proceedings of Singapore Healthcare
Verified
Journal Article
Open access
PDF file
POPei Wen Ong
Pei Wen Ong
TKTerence Kee
Terence Kee
QHQuan Yao Ho
Quan Yao Ho
Background: Calcineurin inhibitors are the cornerstone of maintenance immunosuppression after kidney transplant. While studies on predominantly Caucasian populations recommend tacrolimus over cyclosporine, the effects on Singapore’s local population remain unclear. Objectives: This study aimed to compare the impact of tacrolimus against cyclosporine on post-transplant outcomes in our local kidney transplant population. Methods: A single-centre retrospective chart review was conducted on ABO- and human leucocyte antigen (HLA)-compatible kidney transplantations between 1 January 2011 and 15 August 2018. Patients who received basiliximab induction, prednisolone, mycophenolate and either tacrolimus or cyclosporine were included and followed up for at least one year. Recipients of transplantations at other institutions or other immunosuppressive regimens were excluded. Patient and graft outcomes and adverse effects were collected. Results: Overall, 120 patients on tacrolimus and 49 on cyclosporine were included. Patients on tacrolimus were older. This group had more deceased donor transplants, a higher proportion with donor-specific antibodies (DSAs) present and more HLA mismatches. There were no differences in patient and graft survival, graft function and acute rejections at one year, despite adjusting for age, transplant type, presence of DSAs and total HLA mismatches. The tacrolimus group had more infectious admissions (odds ratio=0.27, 95% confidence interval 0.098–0.73, p=0.01) after adjusting for age, transplant type, HLA mismatches, presence of DSAs and acute rejections, with increased severity and more opportunistic infections. More patients on cyclosporine required a change to alternative immunosuppressants (p=0.003). Conclusion: Our study demonstrated comparable short-term post-transplant outcomes between cyclosporine and tacrolimus. Tacrolimus appears more tolerable but may be associated with infection risks.

7 September 2024 in Cleaner Chemical Engineering
Verified
Journal Article
Open access
KBKunal S. Bapat
Kunal S. Bapat
TKT.P. Kee
T.P. Kee
SRS.J. Russell
S.J. Russell
Long LinLong Lin
Long Lin